We look for potentially undervalued stocks in biotech, technology, and commodities sectors.
The long and short of it.
We perform research, and give investment opinions and ideas to buy-side firms from time to time.
We are not advisors.
Research investment analyst for Chicago consulting firm until 2009. In this role I was the lead analyst on large 401k plans, pensions and endowments totaling over $20 billion in assets. I also headed analyst research on fixed income and hedge fund of funds portfolios. Today, I focus my research on finding value stocks with sound fundamentals and healthy cash flow. I concentrate my personal portfolio on quality dividend growth stocks and keep an active watch list of over 150 stocks to add on pull backs or at an attractive valuation.
I exited the finance industry in 2010 to follow my dream of becoming a firefighter. I now live and work in Texas. I consider myself a value investor and tend to stay away from speculation stocks.
Engineering background with research in biopharmaceuticals. Semi-retired from the workforce to focus on the BioPharma market. I seek out stocks that have either been over-looked or undiscovered and aim to gain entry at a valuated discount to the intrinsic potential of an imminent share price inflection.
65 years old, been trading for almost 40 years. Take a long view, I have 100 % faith in long term fundamentals and use Technicals (MACD/RSI/MOM/Fibonacci) only to gauge entry/exit points.
I believe the bankers and heads of financial institutions responsible for the derivatives mess should all have had lengthy prison sentences of the type handed down to Skilling (Enron) and Ebbers (WorldCom). The District Court Judge said of Skilling:
"His crimes have imposed on hundreds, if not thousands of victims a life sentence of poverty."
And exactly what did the bankers, Goldman Sachs and the others do to have deserved a lesser sentence or even no sentence at all?
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
I am an analyst and 2017 Level III Candidate in the CFA Program that has gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
Ivy League grad, summa cum laude, 4.0 in Economics, Columbia J.D., 20+ years experience identifying early trends and themes b4 the Wall St herd. In search of undervalued, underfollowed, explosive growth opportunities, principally in, but not limited to, the biotech sector.